Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors

JAMA Oncol. 2022 Jun 1;8(6):1-2. doi: 10.1001/jamaoncol.2022.1467.

Authors

Ithai Waldhorn¹, Roy Holland¹, Tal Goshen-Lago¹, Madeleine Benguigui², Michael Halberthal^{2

3}, Yuval Shaked², Irit Ben-Aharon^{1

2}

Affiliations

¹ Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
² Rappaport Faculty of Medicine, Technion, Haifa, Israel.
³ General management, Rambam Health Care Campus, Haifa, Israel.

PMID: 35452089
DOI: 10.1001/jamaoncol.2022.1467

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

BNT162 Vaccine
Humans
Neoplasms*
Vaccines*

Substances

Vaccines
BNT162 Vaccine